Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Price Down 5.5%

Shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) traded down 5.5% during trading on Monday . The company traded as low as $1.38 and last traded at $1.38. 34,402 shares were traded during trading, a decline of 51% from the average session volume of 69,969 shares. The stock had previously closed at $1.46.

Hepion Pharmaceuticals Stock Down 5.5 %

The stock has a market capitalization of $7.55 million, a PE ratio of -0.11 and a beta of 1.72. The company’s fifty day moving average price is $2.17 and its 200-day moving average price is $2.71.

Hepion Pharmaceuticals (NASDAQ:HEPA) last released its earnings results on Tuesday, April 16th. The company reported ($2.42) EPS for the quarter. Equities research analysts anticipate that Hepion Pharmaceuticals, Inc. will post -11.43 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Hepion Pharmaceuticals stock. Armistice Capital LLC increased its holdings in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) by 5.1% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 418,000 shares of the company’s stock after buying an additional 20,393 shares during the quarter. Armistice Capital LLC owned about 9.63% of Hepion Pharmaceuticals worth $1,354,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 17.24% of the company’s stock.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.